Evidence map›Paper›PMID 36760244›Full record

ArticleAnnals of translational medicine2023

ncRNA-mediated low expression of P2RY14 correlates with poor prognosis and tumor immune infiltration in ovarian carcinoma.

Chenggan Shu, Lifen Liu, Xiaoping Chen, Jinling Xue, Jiahong Fei, Jianqing Wang, Xiaoyue Yang, Qi Peng, Huaqin Yuan

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Chenggan Shu *Department of Obstetrics and Gynecology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School & the First People's Hospital of Yancheng, Yancheng, China.
Lifen Liu *Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xiaoping ChenDepartment of Obstetrics and Gynecology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School & the First People's Hospital of Yancheng, Yancheng, China.
Jinling XueDepartment of Obstetrics and Gynecology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School & the First People's Hospital of Yancheng, Yancheng, China.
Jiahong FeiDepartment of Obstetrics and Gynecology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School & the First People's Hospital of Yancheng, Yancheng, China.
Jianqing WangDepartment of Obstetrics and Gynecology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School & the First People's Hospital of Yancheng, Yancheng, China.
Xiaoyue YangDepartment of Obstetrics and Gynecology, Jiangsu University Affiliated People's Hospital, Zhenjiang, China.
Qi PengDepartment of Gynecology and Obstetrics, Yangzhou Jiangdu People's Hospital, Yangzhou, China.
Huaqin YuanDepartment of Oncology, Nanjing Gaochun People's Hospital Affiliated to Yangzhou University, Nanjing, China.
Yancheng First People's Hospital · CNNantong University · CNJiangsu University · CNNorthern Jiangsu People's Hospital · CNSoochow University · CNYangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ovarian cancer (OV) has been puzzling clinicians because of its poor prognosis. More and more evidence show that the G protein coupled receptor P2RY14 plays a key role in the initiation and progression of various types of human cancer. The purpose of our study is to explore the correlation between P2RY14 and the prognosis of ovarian cancer patients and the relevant mechanism. Methods: First, the differentially expressed gene P2RY14 was screened from The Cancer Genome Atlas (TCGA) database. Explored possible P2RY14 related miRNAs and lncRNAs through multiple public databases, predicted and analyzed the expression level of candidate miRNAs and candidate lncRNAs that can bind to candidate miRNAs in OV through StarBase database. The TIMER database was used to comprehensively analyze the expression of tumor infiltrating immune cells, and to analyze the correlation between the expression level of P2RY14 and the level of immune cell infiltration in OV or the expression level of immune checkpoints. Results: Patients with P2RY14 overexpression had better overall survival (OS) and progression-free interval (PFI). In the Targetscan database, 22 upstream miRNAs that may bind to P2RY14 were predicted. According to the regulatory network constructed by the Cytoscape software, correlation analysis and the role of miRNAs in the prognosis of OV, we first determined that the candidate miRNAs were miR-34c-5p. Then, we predicted the upstream lncRNAs of miR-34c-5p in the StarBase database, the expression level of these lncRNAs in OV in the Gene Expression Profiling Interactive Analysis (GEPIA) database, and the role in prognosis. We determined that LINC00665 is the most potential lncRNA upstream of ovarian cancer miRNA (hsa-miR-34c-5p)-P2RY14. Then, we analyzed the results in the Timer database, suggesting that P2RY14 expression was positively correlated with CD8 Conclusions: P2RY14 can be used as a new predictive biomarker of ovarian cancer. Intervention of P2RY14 can affect the prognosis of ovarian cancer by affecting LINC00665-miR-34c-5p-P2RY14 axis. These findings provide a potential target for the development of anti-cancer strategies for ovarian cancer.

Indexed as

LINC00665miR-34c-5povarian cancer (OV)P2RY14prognosis

Identifiers

PMID36760244
PMCPMC9906193
OpenAlexW4313897958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.